Unity Biotechnology Inc

Unity Biotechnology — Technical Presentation (August 2022)

23 slides from Unity Biotechnology's technical presentation, Aug 12, 2022

  1. Slide 1: UBX1325 Phase 2 BEHOLD DME Study 12- and 18-Week Data

    UBX1325 Phase 2 BEHOLD DME Study 12- and 18-Week Data August 12, 2022 Robert Bhisitkul, M.D., Ph.D. Professor of Ophthalmology, UCSF Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO Exhibit 99.2

  2. Slide 2: Special Note Regarding Forward-Looking Statements

    Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to Unity Biotechnology Inc.’s (“UNITY’s”) understanding of cellular senescence and the role it plays in diseases of aging, the pote

  3. Slide 3: UBX1325 Achieved Proof-of-Concept in Patients with Diabetic Macular Edema

    UBX1325 Achieved Proof-of-Concept in Patients with Diabetic Macular Edema (DME) Built on UNITY’s Senescent Cell Biology Platform UBX1325, the first senolytic drug being explored in eye disease, had a favorable safety and tolerability profile, with no evidence of intra-ocular inflammation A single do

  4. Slide 4: UNITY Is Developing Senolytic Medicines to Eliminate Senescent Cells

    UNITY Is Developing Senolytic Medicines to Eliminate Senescent Cells to Restore Vascular Health and Improve Vision DME: Increased senescence burden Retinal vasculature affected Blood retinal barrier (BRB) Breakdown Loss of vision DME treated with Senolytic intended results: Senescent cells removed R

  5. Slide 5: UBX1325 Clinical Program Overview

    UBX1325 Clinical Program Overview Safety & Tolerability Safety & Efficacy 2020 2021 2022 2023 Phase 1 ENVISION Phase 2 nAMD Study BEHOLD Phase 2 DME Study SAD 24-Week Follow-up nAMD 24 Week Follow-up SAD Study - up to 10 µg 4Q ‘21 1H ‘22 2H ‘22 Long-Term Extension DME Proof of Concept Study (First-P

  6. Slide 6: UBX1325 Phase 2 BEHOLD Study Historic Data on DME Patients treated with Standard of Care

    UBX1325 Phase 2 BEHOLD Study Historic Data on DME Patients treated with Standard of Care Differences in Patient Population in Ph1 and Ph2 Studies

  7. Slide 7: Context for 12w DME Data: After Anti-VEGF Effect Has Plateaued

    Context for 12w DME Data: After Anti-VEGF Effect Has Plateaued, Patients Gain Approximately 1 Letter in Subsequent 6 Months on Aflibercept Treatment VISTA BLA 125387 Suppl 48, 25 Mar 2015

  8. Slide 8: Comparing Patient Populations Between UBX1325 Phase 1 Study and Phase 2 BEHOLD Study

    Comparing Patient Populations Between UBX1325 Phase 1 Study and Phase 2 BEHOLD Study Phase 1 Design Patients with advanced DME and nAMD No previous anti-VEGF treatment for ≥3 months and for whom anti-VEGF agents were no longer considered beneficial Phase 2 (BEHOLD) Design Patients with DME with resi

  9. Slide 9: UBX1325 Phase 2 BEHOLD Study 12- and 18-Week Data in Patients With DME

    UBX1325 Phase 2 BEHOLD Study 12- and 18-Week Data in Patients With DME

  10. Slide 10: BEHOLD Study Design, Patient Population, and Endpoints

    BEHOLD Study Design, Patient Population, and Endpoints Individuals with Diabetic Macular Edema (with moderate diabetic proliferative retinopathy or better), residual retinal fluid (≥300 µm) and visual acuity deficit (73 ETDRS letters or worse) despite having received repeated anti-VEGF treatments (≥

  11. Slide 11: BEHOLD Study Endpoints and Methodology

    BEHOLD Study Endpoints and Methodology BEHOLD Endpoints: Safety and Tolerability Visual Acuity by Best Corrected Visual Acuity (BCVA, ETDRS Letters) Macular Edema Central Subfield Thickness (CST, µm) Proportion of patients receiving rescue Methodology For all analyses, the primary data sets included

  12. Slide 12: 12- and 18-Week BCVA Mean Changes From Baseline Based on MMRM Analysis

    12- and 18-Week BCVA Mean Changes From Baseline Based on MMRM Analysis Table: VAL_t_14_2_1_23; Figure: VAL_ f_14_2_1_5 BCVA Sham UBX1325 Diff P-Value Week 12 1.3 4.7 3.4 0.1148* Week 18 1.1 6.1 5.0 0.0368** * **

  13. Slide 13: 12- and 18-Week CST Mean Changes From Baseline Based on MMRM Analysis

    12- and 18-Week CST Mean Changes From Baseline Based on MMRM Analysis Table: VAL_t_14_2_1_24; Figure: VAL_14_2_1_6 CST Sham UBX1325 Diff P-Value Week 12 40.3 -1.4 -41.7 0.0747* Week 18 53.5 3.2 -50.2 0.0719** * **

  14. Slide 14: Study Met Statistical Significance Based on Pre-specified Proof of Concept Criteria

    Study Met Statistical Significance Based on Pre-specified Proof of Concept* Criteria for Both BCVA and CST PoC criteria were met for BCVA and CST at Week 12 based on p-values Treatment effect improved through Week 18 Numerically greater use of rescue on Sham vs UBX1325 (12 vs 10 subjects with ≥1 res

  15. Slide 15: Summary of Subgroup Analyses

    Summary of Subgroup Analyses In BEHOLD, 4 subgroup factors with 8 total subgroups (2 each) were evaluated based on baseline values for: BCVA (≤60 vs. >60 ETDRS letters) CST (≤400 vs. >400µm) DRSS Score (<47 vs. ≥47) A1c (≤7 vs. >7%) For the response of BCVA, there was a numeric advantage in all 8 su

  16. Slide 16: Proportion of Subjects Requiring Anti-VEGF Rescue Through Weeks

    Proportion of Subjects Requiring Anti-VEGF Rescue Through 12 Weeks VAL_f_14_2_4_1 UBX1325 Sham Rescue Criteria (Either Triggers Rescue): Increase in CST of +75µm from the lowest value (trough) Decrease in BCVA of -10 ETDRS letters from the highest value (peak)

  17. Slide 17: Summary of Treatment Emergent Adverse Events

    Summary of Treatment Emergent Adverse Events Source data: VAL_t_14_3_1_1; VAL_t_14_3_1_2 Sham (%) (N = 33) UBX1325 10 µg (%) (N = 32) Overall (%) (N = 65) Subjects with at least one TEAE 21 (63.6) 20 (62.5) 41 (63.1) Related TEAE 3 (9.1) 6 (18.8) 9 (13.8) Grade ≥3 TEAE 3 (9.1) 2 (6.3) 5 (7.7) Seriou

  18. Slide 18: Examples of Imaging Data

    Examples of Imaging Data Normal Optical Coherence Tomograph (OCT)

  19. Slide 19: Patient A: Weeks Post Single Injection of UBX1325

    PATIENT A Weeks Post Single Injection of UBX1325 BL 4 8 Weeks Post Single Injection of UBX1325 12 From Baseline to Week 12: Decrease in IRF Decrease in SRF Decrease in volume Decrease in CST ~85 microns Source: Duke Reading Center Images assessed by an independent unmasked image reader

  20. Slide 20: Patient B: Weeks Post Single Injection of UBX1325

    PATIENT B Weeks Post Single Injection of UBX1325 BL 4 8 Weeks Post Single Injection of UBX1325 12 From Baseline to Week 12: Decrease in IRF Decrease in volume (mm3) ~10% Decrease in CST ~250 microns Source: Duke Reading Center Images assessed by an independent unmasked image reader

  21. Slide 21: A Single Injection of UBX1325 Demonstrated Evidence of a Senolytic Agent Improving Visual Acuity

    A Single Injection of UBX1325 Demonstrated Evidence of a Senolytic Agent Improving Visual Acuity in Patients with Diabetic Macular Edema Was well tolerated with a favorable safety profile and no intraocular inflammation Improved BCVA that was durable through 18-weeks Maintained retinal structure vs.

  22. Slide 22: 1325 Program Overview and Data Readouts 2022-24

    2022 2023 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D LPI LPLV LPLV DME 1325-02 TLR DBL TLR DBL 1325-01 Ph1 SAD 12/18w efficacy analysis AMD 1325-03 LPI 16w efficacy analysis 24w follow-up DME Pivotal Study 48w follow-up TLR DBL 24

  23. Slide 23: Key Highlights from Phase 2 BEHOLD DME Study 12- and 18-week data

    Key Highlights from Phase 2 BEHOLD DME Study 12- and 18-week data underscore the therapeutic potential of UBX1325 Visual Acuity Improvement Control of Macular Edema Impact on Retinal Structure

Unity Biotechnology — Technical Presentation (August 2022) on 6ix